Market Breakdown: Alphabet, Humana, Boeing and more

Alphabet, Facebook — Alphabet shares tanked more than 6% after news that the Justice Department was preparing an antitrust lawsuit against Google. According to reports, the probe would look into Google’s search practices and other businesses. Facebook shares also fell 7.5% amid worries of the broader tech sector falling under greater government scrutiny.

Amgen, Mirati Therapeutics — Shares of biotech company Amgen jumped 3.4% after results from a cancer study examining Amgen’s gene therapy drug showed significant reduction in the size of tumors in patients with advanced lung cancer. Promising results also drove shares of Mirati up 31.6% as the biotech company is also developing a drug that targets the same gene mutation.

DuPont — Shares of DuPont jumped 17.8% after a Morgan Stanley analyst initiated coverage of the chemical company with an overweight rating. The analyst said it sees value in DuPont regardless of whether it becomes a “true multi-industry” company or keeps its businesses separated.

Read the full article at CNBC.

Don’t Stop Here

More To Explore

Market Brief: AI Risks and Fed Minutes Incoming

Market Snapshot Market Pulse: U.S. stocks edged sideways, buoyed by fresh AI chatter that kept tech afloat while industrial sectors shrugged off supply-chain jitters. Bond

AARD: 56% Drop Sparks Urgent Investor Scrutiny!

Overview: Aardvark Therapeutics, Inc. (Nasdaq: AARD) is a clinical-stage biotech focused on therapies for metabolic diseases and Prader-Willi Syndrome (PWS) – a rare genetic disorder

Gene-Editing Goldrush Meets AI and ETF Plays

Opening Recap Market Pulse: Gene-editing fervor rippled through biotech circles after a Mordor Intelligence report flagged double-digit growth in cell line development through 2031. Down